secwatch.observer — SEC 8-K summary
======================================

Issuer:     TALPHERA, INC. (TLPH)
CIK:        0001427925
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001437749-23-023035
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AcelRx Q2 net loss $4.4M; raises $10M in private placement; Niyad EUA pending
-----------------------------------------------------------------------------

- Net loss attributable to common shareholders $4.4M ($0.40/share) vs net income $63.2M in Q2 2022.
- Cash and cash equivalents $7.4M at June 30; proforma $17.4M after July private placement.
- Closed $10M private placement led by Nantahala Capital, with potential $16.3M from warrants tied to milestones.
- EUA for Niyad (nafamostat mesylate) submitted to FDA in April; responses awaited. Registrational study to start Q4 2023.
- DSUVIA divested to Alora in April; AcelRx receives 15% royalty on commercial sales, 75% on DoD sales, up to $116.5M milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427925/000143774923023035/0001437749-23-023035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427925/000143774923023035/acrx20230809_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-023035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer